These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 14667993)

  • 1. Pharmacologic properties of CDB(VA)-2914.
    Gainer EE; Ulmann A
    Steroids; 2003 Nov; 68(10-13):1005-11. PubMed ID: 14667993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiovulatory and postcoital antifertility activity of the antiprogestin CDB-2914 when administered as single, multiple, or continuous doses to rats.
    Reel JR; Hild-Petito S; Blye RP
    Contraception; 1998 Aug; 58(2):129-36. PubMed ID: 9773268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDB-2914: anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits.
    Hild SA; Reel JR; Hoffman LH; Blye RP
    Hum Reprod; 2000 Apr; 15(4):822-9. PubMed ID: 10739827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914.
    Attardi BJ; Burgenson J; Hild SA; Reel JR; Blye RP
    Mol Cell Endocrinol; 2002 Feb; 188(1-2):111-23. PubMed ID: 11911951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progesterone receptor modulators.
    Bhathena R
    J Fam Plann Reprod Health Care; 2010 Jul; 36(3):179; author reply 179. PubMed ID: 20659379
    [No Abstract]   [Full Text] [Related]  

  • 6. A practical large-scale synthesis of 17alpha-acetoxy-11beta-(4-N, N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione (CDB-2914).
    Rao PN; Acosta CK; Bahr ML; Burdett JE; Cessac JW; Morrison PA; Kim HK
    Steroids; 2000 Jul; 65(7):395-400. PubMed ID: 10899539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone.
    Attardi BJ; Burgenson J; Hild SA; Reel JR
    J Steroid Biochem Mol Biol; 2004 Mar; 88(3):277-88. PubMed ID: 15120421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women.
    Stratton P; Hartog B; Hajizadeh N; Piquion J; Sutherland D; Merino M; Lee YJ; Nieman LK
    Hum Reprod; 2000 May; 15(5):1092-9. PubMed ID: 10783359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of progesterone receptor modulators and their effect on the endometrium.
    Spitz IM
    Curr Opin Obstet Gynecol; 2009 Aug; 21(4):318-24. PubMed ID: 19602929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis.
    Wiehle R; Lantvit D; Yamada T; Christov K
    Cancer Prev Res (Phila); 2011 Mar; 4(3):414-24. PubMed ID: 21119048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular properties and preclinical pharmacology of JNJ-1250132, a steroidal progesterone receptor modulator that inhibits binding of the receptor to DNA in vitro.
    Allan GF; Palmer E; Musto A; Lai MT; Clancy J; Palmer S
    Steroids; 2006 Jul; 71(7):578-84. PubMed ID: 16597452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications.
    Blithe DL; Nieman LK; Blye RP; Stratton P; Passaro M
    Steroids; 2003 Nov; 68(10-13):1013-7. PubMed ID: 14667994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating concentrations of the antiprogestins CDB-2914 and mifepristone in the female rhesus monkey following various routes of administration.
    Larner JM; Reel JR; Blye RP
    Hum Reprod; 2000 May; 15(5):1100-6. PubMed ID: 10783360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 11 beta-substituted 13 beta-ethyl gonane derivatives exhibit reversal of antiprogestational activity.
    Rao PN; Cessac JW; Blye RP; Kim HK
    Steroids; 1998 Jan; 63(1):50-7. PubMed ID: 9437795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiprogestins: mechanism of action and contraceptive potential.
    Spitz IM; Croxatto HB; Robbins A
    Annu Rev Pharmacol Toxicol; 1996; 36():47-81. PubMed ID: 8725382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780.
    Wu Y; Guo SW
    Gynecol Obstet Invest; 2006; 62(4):193-205. PubMed ID: 16778450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progesterone antagonists and progesterone receptor modulators: an overview.
    Spitz IM
    Steroids; 2003 Nov; 68(10-13):981-93. PubMed ID: 14667991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Molecular Changes in Endometrium Associated With Chronic Use of Progesterone Receptor Modulators: Ulipristal Acetate Versus Mifepristone.
    Kannan A; Bhurke A; Sitruk-Ware R; Lalitkumar PG; Gemzell-Danielsson K; Williams ARW; Taylor RN; Bagchi MK; Bagchi IC
    Reprod Sci; 2018 Mar; 25(3):320-328. PubMed ID: 29241443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of N-desmethyl derivatives of 17alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-die ne-3,20-dione and mifepristone1: substrates for the synthesis of radioligands.
    Rao PN; Acosta CK; Cessac JW; Bahr ML; Kim HK
    Steroids; 1999 Mar; 64(3):205-12. PubMed ID: 10400381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mifepristone: a potential clinical agent based on its anti-progesterone and anti-glucocorticoid properties.
    Sun Y; Fang M; Davies H; Hu Z
    Gynecol Endocrinol; 2014 Mar; 30(3):169-73. PubMed ID: 24205903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.